Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Ann Arbor Stage IB Hodgkin Lymphoma: early-phase trial registry

A small indexed set (3 trials) with no open enrollment listed right now.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count

Ann Arbor Stage IB Hodgkin Lymphoma: 3 US clinical trials tracked, none currently recruiting.

Ann Arbor Stage IB Hodgkin Lymphoma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Academic and Community Cancer Research United, running 2 of these trials.

Enrollment posture brief

Registry condition ann-arbor-stage-ib-hodgkin-lymphoma

OPEN 0 | RECR 0% | LATE 0 | EARLY 3 | RANK #5209 | SPON 2

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Ann Arbor Stage IB Hodgk (th…0%
Open-enrollment share among volume-matched conditions near Ann Arbor Stage IB Hodgkin Lymphoma

Ann Arbor Stage IB Hodgkin Lymphoma has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Ann Arbor Stage IB Hodgkin Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Ann Arbor Stage IB Hodgkin Lymphoma is recruiting below its size-band peers.

    0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 23

Phase Distribution

PhaseTrial count
Phase 2 3

Named interventions

Most-linked intervention names on Ann Arbor Stage IB Hodgkin Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Brentuximab Vedotin Drug
3 trials
Nivolumab Biological
3 trials
Dacarbazine Drug
2 trials
Doxorubicin Drug
2 trials
Bleomycin Drug
1 trials
Laboratory Biomarker Analysis Other
1 trials

US sites by state

Facility locations filed on Ann Arbor Stage IB Hodgkin Lymphoma trials. A trial with sites in several states counts in each.

Texas 3 trials
New Jersey 3 trials
California 3 trials
Tennessee 2 trials
Pennsylvania 2 trials
Ohio 2 trials
New York 2 trials
Minnesota 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Ann Arbor Stage IB Hodgkin Lymphoma page

3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ann Arbor Stage IB Hodgkin Lymphoma condition card totals 3 registered trials; most-linked intervention Brentuximab Vedotin; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.